BioPharmSignal logoBioPharmSignal

Biotech News

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

bioAffinity Technologies, Inc. (BIAF)bioAffinity Technologies, Inc.Company update

BIAF (BIAF) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is biaf.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

BIAFbioAffinity Technologies, Inc.2026-07-27 12:08 EST

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-06-02 12:00 EST

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

View all latest news

bioAffinity Technologies, Inc.

bioAffinity Technologies is a diagnostic company focused on noninvasive testing and lung-cancer detection. Its business is built around using biomarkers and cell-based analysis to support earlier disease identification.

Recent company news

BIAFbioAffinity Technologies, Inc.2026-07-27 12:08 EST

bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung

BIAFbioAffinity Technologies, Inc.2026-07-22 12:08 EST

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

BIAFbioAffinity Technologies, Inc.2026-07-07 12:46 EST

bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues

BIAFbioAffinity Technologies, Inc.2026-06-22 12:00 EST

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

BIAFbioAffinity Technologies, Inc.2026-06-18 17:16 EST

bioAffinity Technologies Announces Closing of $3.2 Million Offering

Stock data

Close
0.63 USD
Market cap
7.62M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States